Physician profile
Atoussa Farough
NPI 1902063720
$5,244.44
in general payments reported to CMS, 2019-2025
45 companies · $1,043 in 2025
The $1,043 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2020: $419 · 2021: $727 · 2022: $354 · 2023: $795 · 2024: $1,063 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,900.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,069.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $668.62 | 2019-2025 | |
| Lilly USA, LLC | $643.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $461.91 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $273.39 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $210.89 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $193.05 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $173.42 | 2019-2024 | Dificid, Gardasil, Capvaxive |
| Astellas Pharma US INC | $139.04 | 2019-2025 | Veozah |
| Medtronic Vascular, INC. | $114.09 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $90.93 | 2019-2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $89.17 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $86.88 | 2023-2025 | Rexulti, Nuedexta |
| Mylan Specialty L.P. | $83.00 | 2021-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.99 | 2019-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atoussa Farough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.